UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 129

Sortiert nach

Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire

Multiple sclerosis, 2008-08, Vol.14 (7), p.940-946

2008

Volltextzugriff (PDF)

Management of Multiple Sclerosis

The New England journal of medicine, 1997-11, Vol.337 (22), p.1604-1611

1997

Volltextzugriff (PDF)

Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures

Multiple sclerosis, 2012-08, Vol.18 (8), p.1074-1080

2012

Volltextzugriff (PDF)

Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing−remitting multiple sclerosis: A retrospective analysis

Multiple sclerosis, 2016-04, Vol.22 (5), p.668-676

2016

Volltextzugriff (PDF)

Defining interferon β response status in multiple sclerosis patients

Annals of neurology, 2004-10, Vol.56 (4), p.548-555

2004

Volltextzugriff (PDF)

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks

Multiple sclerosis, 2010-11, Vol.16 (11), p.1385-1392

2010

Volltextzugriff (PDF)

Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study

Multiple sclerosis, 2010-05, Vol.16 (5), p.588-596

2010

Volltextzugriff (PDF)

The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment

Multiple sclerosis, 1999-08, Vol.5 (4), p.244-250

1999

Volltextzugriff (PDF)

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS

Neurology, 2001-10, Vol.57 (7), p.1239

2001

Volltextzugriff (PDF)

Eight-year follow-up study of brain atrophy in patients with MS

Neurology, 2002-11, Vol.59 (9), p.1412

2002

Volltextzugriff (PDF)

Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis

Neurology, 2005-03, Vol.64 (6), p.992

2005

Volltextzugriff (PDF)

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

Brain (London, England : 1878), 1999-05, Vol.122 (5), p.871-882

1999

Volltextzugriff (PDF)

Axonal loss in normal-appearing white matter in a patient with acute MS

Neurology, 2001-10, Vol.57 (7), p.1248

2001

Volltextzugriff (PDF)

Assessing disability progression with the Multiple Sclerosis Functional Composite

Multiple sclerosis, 2009-08, Vol.15 (8), p.984-997

2009

Volltextzugriff (PDF)

CAN WE RELIABLY USE MRI TO MONITOR TREATMENT RESPONSE IN PATIENTS ON INTERFERON [beta]: A SYSTEMATIC REVIEW AND META-ANALYSIS

Journal of neurology, neurosurgery and psychiatry, 2012-11, Vol.83, p.A34

2012

Volltextzugriff (PDF)

CAN WE RELIABLY USE MRI TO MONITOR TREATMENT RESPONSE IN PATIENTS ON INTERFERON β: A SYSTEMATIC REVIEW AND META-ANALYSIS

Journal of neurology, neurosurgery and psychiatry, 2012-11, Vol.83 (Suppl 2), p.A34-A34

2012

Volltextzugriff (PDF)

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS

Neurology, 2002-09, Vol.59 (5), p.679

2002

Volltextzugriff (PDF)

Association of fatigue and brain atrophy in multiple sclerosis

Journal of the neurological sciences, 2005-02, Vol.228 (2), p.161-166

2005

Volltextzugriff (PDF)

In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis

Neurology, 1998-05, Vol.50 (5), p.1294

1998

Volltextzugriff (PDF)

Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS

Neurology, 2001-05, Vol.56 (10), p.1324

2001

Volltextzugriff (PDF)

T‐cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking

Clinical and experimental immunology, 2002-09, Vol.129 (3), p.510-518

2002

Volltextzugriff (PDF)

Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients

Multiple sclerosis, 2000-12, Vol.6 (6), p.373-377

2000

Volltextzugriff (PDF)

Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis

European journal of neurology, 2005-07, Vol.12 (7), p.550-556

2005

Volltextzugriff (PDF)

Primary progressive multiple sclerosis as a phenotype of a PLP1 gene mutation

Annals of neurology, 2005-09, Vol.58 (3), p.470-473

2005

Volltextzugriff (PDF)

Change in quality of life in patients with relapsing–remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon β-1a

Multiple sclerosis, 2011-06, Vol.17 (6), p.734-742

2011

Volltextzugriff (PDF)

1 – 25 von 129

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(103)
Mit Volltextzugriff
(81)

Publikationsform

Artikel
(127)
magazinearticle
(2)

Sprache

Englisch
(129)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Repeated assessment of neuropsychological deficits in multiple sclerosis using the Symbol Digit Modalities Test and the MS Neuropsychological Screening Questionnaire

Management of Multiple Sclerosis

Revisiting The Multiple Sclerosis Functional Composite: proceedings from the National Multiple Sclerosis Society (NMSS) Task Force on Clinical Disability Measures

Effect of intramuscular interferon beta-1a on gray matter atrophy in relapsing−remitting multiple sclerosis: A retrospective analysis

Defining interferon β response status in multiple sclerosis patients

Evaluation of the symbol digit modalities test (SDMT) and MS neuropsychological screening questionnaire (MSNQ) in natalizumab-treated MS patients over 48 weeks

Intramuscular interferon beta-1a therapy in patients with relapsing-remitting multiple sclerosis: a 15-year follow-up study

The Multiple Sclerosis Functional Composite measure (MSFC): an integrated approach to MS clinical outcome assessment

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS

Eight-year follow-up study of brain atrophy in patients with MS

Low-contrast letter acuity testing captures visual dysfunction in patients with multiple sclerosis

Development of a multiple sclerosis functional composite as a clinical trial outcome measure

Axonal loss in normal-appearing white matter in a patient with acute MS

Assessing disability progression with the Multiple Sclerosis Functional Composite

CAN WE RELIABLY USE MRI TO MONITOR TREATMENT RESPONSE IN PATIENTS ON INTERFERON [beta]: A SYSTEMATIC REVIEW AND META-ANALYSIS

CAN WE RELIABLY USE MRI TO MONITOR TREATMENT RESPONSE IN PATIENTS ON INTERFERON β: A SYSTEMATIC REVIEW AND META-ANALYSIS

Benefit of interferon beta-1a on MSFC progression in secondary progressive MS

Association of fatigue and brain atrophy in multiple sclerosis

In vivo effects of interferon beta-1a on immunosuppressive cytokines in multiple sclerosis

Use of the Multiple Sclerosis Functional Composite to predict disability in relapsing MS

T‐cells in the cerebrospinal fluid express a similar repertoire of inflammatory chemokine receptors in the absence or presence of CNS inflammation: implications for CNS trafficking

Relationship between brain atrophy and disability: an 8-year follow-up study of multiple sclerosis patients

Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis

Primary progressive multiple sclerosis as a phenotype of a PLP1 gene mutation

Change in quality of life in patients with relapsing–remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon β-1a

Suchergebnisse filtern